Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 7;8(3):31.
doi: 10.3390/diseases8030031.

Fosfomycin, Applying Known Methods and Remedies to A New Era

Affiliations

Fosfomycin, Applying Known Methods and Remedies to A New Era

Viviana Albán M et al. Diseases. .

Abstract

The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as part of a combined therapy scheme. However, the assessment of fosfomycin susceptibility in the laboratory presents a great challenge due to the discrepancies found between different methodologies. Thus, our goal was to evaluate fosfomycin susceptibility in a group of 150 Enterobacteriaceae bacterial isolates using agar dilution as the gold standard technique to compare the results with those obtained by disk diffusion. We found a fosfomycin susceptibility of 79.3% in general terms. By comparing both methodologies, we reported a categorical agreement of 96% without Very Major Errors (VMEs) or Major Errors (MEs) and 4% of minor Errors (mEs). Our results suggest that fosfomycin could provide a rational alternative treatment for those patients that are infected by a Multidrug-Resistant (MDR) microorganism that is currently untreatable and that the disk diffusion and classical agar dilution techniques are adequate to assess the resistance profile of CRE to fosfomycin.

Keywords: agar dilution; carbapenem-resistant Enterobacteriaceae (CRE); disk diffusion; fosfomycin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Scatter plot representing clinical errors between disk diffusion and agar technique.

References

    1. Logan L.K., Weinstein R.A. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J. Infect. Dis. 2017;215(suppl. 1):S28–S36. doi: 10.1093/infdis/jiw282. - DOI - PMC - PubMed
    1. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. doi: 10.1111/j.1469-0691.2011.03570.x. - DOI - PubMed
    1. Raz R. Fosfomycin: An old—New antibiotic. Clin. Microbiol. Infect. 2012;18:4–7. doi: 10.1111/j.1469-0691.2011.03636.x. - DOI - PubMed
    1. Borisova M., Gisin J., Mayer C. Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin. Microb. Drug Resist. 2014;20:231–237. doi: 10.1089/mdr.2014.0036. - DOI - PMC - PubMed
    1. Hashemian S.M.R., Farhadi Z., Farhadi T. Fosfomycin: The characteristics, activity, and use in critical care. Ther. Clin. Risk Manag. 2019;15:525–530. doi: 10.2147/TCRM.S199119. - DOI - PMC - PubMed

LinkOut - more resources